All
‘Don’t Sugarcoat Things’ When Someone You Know is Diagnosed with Metastatic Breast Cancer
October 21st 2020“Most kinds of breast cancer are potentially curable, but metastatic breast cancer is not,” says Kathleen Friel, lab director at the Burke Neurological Institute of Weill Cornell Medicine. “People assume, ‘Oh, you must be fine because you look fine.’ It puts a lot of expectations on us that, if somehow we’re strong enough, then we’ll beat this disease.”
Aliqopa in Combination with Rituxan Meets Primary End Point for Indolent Non-Hodgkin’s Lymphoma
October 16th 2020A study evaluating the efficacy of Aliqopa (copanlisib) in combination with Rituxan (rituximab) in patients with indolent non-Hodgkin’s lymphoma who have relapsed after at least one prior line of therapy also involving Rituxan has met its primary endpoint, according to Aliqopa’s manufacturer, Bayer.
Actor Sterling K. Brown is the Face of ‘Survivorship Today’ Shedding Light on Life After Cancer
October 15th 2020Through Bristol Myers Squibb’s ‘Survivorship Today,’ Brown — a star of the TV series “This Is Us” — has been interviewing cancer survivors about their journeys and the kinds of support they need.
FDA Approves Keytruda for the Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma
October 15th 2020Data from the trial that led to the FDA approval demonstrated that Keytruda reduced the risk of progression or death in patients with relapsed or refractory classical Hodgkin lymphoma by 35%, compared to Adcetris.
Mortality From COVID-19 Increases in Patients Receiving Systemic Cancer Treatments
October 14th 2020In an interview with CURE®, Dr. Trisha Wise-Draper discusses new findings that show an increased mortality risk for patients with cancer receiving systemic treatments who subsequently contracted COVID-19.
Dose-Dense Chemotherapy Improves Disease-Free Survival in HR+/HER2- Breast Cancer
October 13th 2020Researchers found that neoadjuvant chemotherapy with intense dose-dense Ellence (epirubicin), Taxol (paclitaxel), and Cytoxan (cyclophosphamide) (iddEPC) demonstrated significant disease-free survival benefits in the treatment of patients with HR+/HER2- breast cancer.